2012
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. Journal Of Cystic Fibrosis 2012, 12: 147-153. PMID: 22944725, PMCID: PMC3696392, DOI: 10.1016/j.jcf.2012.08.001.Peer-Reviewed Original ResearchConceptsPulmonary exacerbationsCF patientsP. aeruginosa eradicationP. aeruginosa isolationCystic fibrosis patientsEarly P. aeruginosaBaseline seropositivityEPIC trialPositive serologyAntibiotic therapyChild TrialTreatment failurePrognostic valuePseudomonas infectionWeek 10Fibrosis patientsSerologyCulture resultsPatientsClinicians' effortsExacerbationSeropositivityP. aeruginosaRiskTrials
2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo